Introduction

The retroaortic course of the left innominate vein is a rare entity which can be misinterpreted during echocardiography for other abnormal vascular structures under the aortic arch. We reported the case of a 2-week-old female infant whose echocardiogram showed coarctation of the aorta and 2 vascular structures beneath the hypoplastic left aortic arch, one of which was traced to be a retroaortic left innominate vein. Right aortic arch is a common association. More than 80% of the patients with anomalous retroaortic left innominate vein have obstruction of the right ventricular outflow tract (Tetralogy of Fallot). However, our patient has a left sided aortic arch with hypoplastic transverse arch and juxtaductal coarctation of aorta without any right ventricular outflow tract obstruction.

Case

A newborn girl with prenatal diagnosis of hypoplastic aortic valve and hypoplastic aortic arch on fetal echocardiogram was delivered at a referring hospital. Her initial postnatal echocardiogram was read as normal for age with a patent ductus arteriosus; the patient was discharged home with a cardiology follow-up appointment. However, after missing her appointment, she presented to the Emergency Department in cardiogenic shock at 2 weeks of age. She was hypotensive, tachycardic and tachypneic with cold extremities on presentation. Pulses were diminished in lower extremities with poor perfusion. She was intubated and started on mechanical ventilation due to worsening respiratory distress. Coarctation of aorta was suspected based on physical exam. Her initial echocardiography showed juxtaductal Coarctation of the aorta, tiny Patent Ductus Arteriosus (PDA) and mildly impaired left ventricular function. The patient was immediately started on intravenous prostaglandin E1, inotropic support, and metabolic acidosis was corrected.

Once patient was stabilized, a repeat complete echocardiogram demonstrated bicuspid aortic valve, juxtaductal coarctation of the aorta, patent ductus arteriosus, hypoplastic left aortic arch and two retroaortic vessels; the upper vessel being smaller in size was identified as the left innominate vein (Figure 1). Typically, there is only one vessel under the aortic arch, the right pulmonary artery. The differential diagnosis of an additional vessel in the suprasternal windows include an aorto-pulmonary collateral, a PDA arising from aortic arch, persistent fifth aortic
The Nit-Occlud® coil system for PDA closure is designed to match individual morphologies and sizes.

The delivery system facilitates optimal device positioning.

The Nit-Occlud® PDA coil is repositionable and retrievable prior to release.

Tight and compact windings ensure efficient occlusion.

Radiopaque

For more information or to place an order, contact your B. Braun Interventional Systems Inc. representative or call 1-877-VENA-CAV (836-2228)

Manufacturer:
pfm medical, ag
Wankelstraße 60
50996 Köln, Germany
T +49 (0)2236 9641-10
F +49 (0)2236 9641-20

Distributed by:
B. Braun Interventional Systems Inc.
824 Twelfth Avenue
Bethlehem, PA 18018 USA
Tel: 1-877-VENA-CAV (836-2228) (USA)
Fax: 1-610-849-1334
www.bisusa.org

For more information or to place an order, contact your B. Braun Interventional Systems Inc. representative or call 1-877-VENA-CAV (836-2228)
arch, the vertical vein in supracardiac-type of Total Anomalous Pulmonary Venous Connection (TAPVC), and venous structures such as a retro-aortic innominate vein. Doppler interrogation demonstrated continuous low velocity pattern suggestive of venous structure. The probe was tilted leftward and anteriorly to trace the vessel which revealed venous flow from the left side of the neck passing below the aorta, directed to the right side and draining into the superior vena cava (Figure 2), confirming the diagnosis of retro-aortic left innominate vein.

The patient underwent a computerized topographic angiogram to assess the aortic arch which showed diffuse left aortic arch hypoplasia (3 mm) beyond the origin of the innominate artery with mild focal discrete juxtaductal coarctation of the aorta (2.5 mm) just distal to the left subclavian artery. Also, poststenotic dilation of the descending thoracic aorta (7 mm) and low origin of the left subclavian artery was noted (Figure 3).

The patient underwent coarctation of the aorta and hypoplastic aortic arch repair with bovine pericardium via a left lateral thoracotomy. The patient had an uneventful postoperative course.

Discussion

The left innominate vein normally courses obliquely downward to the right passing superoanterior to the aortic arch, and in front of its branches to drain into superior vena cava. Retro-aortic innominate vein is a rare entity where the innominate vein takes an anomalous course below the aortic arch with an incidence of 0.2-1.0% among congenital cardiac anomalies. Right aortic arch is also a common association. More than 80% of the patients with anomalous retroaortic left innominate vein have obstruction of the right ventricular outflow tract (Tetralogy of Fallot). However, our patient has a left-sided aortic arch with a hypoplastic transverse arch and juxtaductal coarctation of the aorta, without any right ventricular outflow tract obstruction. One such case is described in literature so far.

Embryologically, as most of the left cardinal veins disappear, the venous drainage from the left side of the head and neck and the left arm is directed into the right anterior cardinal vein by 2 transverse capillary plexi above and below the fourth aortic arch. Normally, the aortic arch shortens during the embryological development and occupies the space of the inferior transverse capillary plexus, thus causing its regression. The rest of the venous blood shunts into the superior transverse capillary plexus, and forms the normal supraortic course of the left innominate vein. In contrast, reduced shortening of the aortic arch (right-sided or
PROVEN PERFORMANCE. SIMPLY DELIVERED.

MELODY TPV DELAYS CONDUIT REPLACEMENT

98%
Patients at 2 years

91%
Patients at 5 years

Data from US IDE Study

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use.
high aortic arch) may cause regression of the superior capillary plexus and results in preservation of the inferior capillary plexus and formation of the retroaortic vein (Figure 4). Abnormal development of the pulmonary arteries (pulmonary atresia or pulmonary stenosis) encourages the sparing of the lower dorsal plexus, leading to formation of an anomalous innominate vein.1

The retroaortic innominate vein can usually be traced by echocardiography in the suprasternal long axis view to the left side of neck when the transducer is tilted leftwards and anteriorly. Doppler color flow and Doppler spectral analysis shows low velocity venous flow into the superior vena cava.3 An aorto-pulmonary collateral and PDA arising from the aortic arch show a high velocity continuous flow.

Usually, the retroaortic innominate vein in isolation has no clinical importance. The anomalous innominate vein may cause technical difficulties during pacemaker insertion or central venous line placement through the left arm approach. For patients undergoing cardiac surgery, the superior vena cava cannulation for cardiopulmonary bypass has to be done more caudally than usual to avoid obstruction of the retroaortic innominate vein.1 The anomaly may complicate exposure of the pulmonary arteries while creating systemic vein to pulmonary artery anastomosis during Glenn shunt. Also, it may obscure the surgical field in the construction of a subclavian to pulmonary artery shunt and the ligation of a patent ductus arteriosus.4 Retroaortic innominate vein has been used in pulmonary artery reconstruction by creating a wide side-to-side anastomosis.5

References


Figure 2. Suprasternal view showing retroaortic left innominate vein venous flow from the left side of the neck passing below the aorta to the right side.

Figure 3. CT angiogram, Figure 3a-lateral view and Figure 3b-3D reconstruction showing hypoplastic left aortic arch, juxtaductal coarctation of aorta, patent ductus arteriosus and low origin of left subclavian artery just proximal to the coarctation site.

How We Operate

Volunteer / Get Involved

www.chimsupport.com

The team involved at C.H.I.M.S. is largely a volunteering group of physicians, nurses and technicians who are involved in caring for children with congenital heart disease.

The concept is straightforward. We are asking all interested catheter laboratories to register and donate surplus inventory which we will ship to help support CHD mission trips to developing countries.


CHiP Network Update

By Gary Webb, MD

The basic idea of the CHiP Network (Congenital Heart Professionals Network) is that congenital heart and pediatric cardiac professionals can subscribe to the service, indicating the type of information they would like to receive. This builds a list that is global, and that can be used by approved/appropriate organizations to communicate with professional members of this community. As a result, these organizations will be able to communicate with a larger readership. There is no charge for the service.

The CHiP Network has the capacity to send information only to certain types of professionals, in certain countries or cities, and to subscribers requesting messages in languages other than English. The potential of the system is still being explored. The CHiP Network is all-inclusive and is comprised of everyone who considers themselves a congenital heart or pediatric cardiac professional or administrator, including:

- Pediatric cardiologists
- ACHD cardiologists
- Cardiac surgeons
- RNs and APNs
- Physician assistants
- Cardiac care associates
- Trainees/fellows
- Administrators
- Social workers
- Psychologists and mental health professionals
- Researchers/scientists
- Transition medicine specialists
- Intensivists
- Anesthetists
- and Industry representatives.

This will make it possible for these various groups to communicate with people who identify themselves as being in the same profession. Of course, individuals in those groups will need to initiate the communications and consider how best to do this.

This will enable the circulation of various types of information:

- pending events
- Journal Watch
- research opportunities
- educational resource announcements
- news stories
- and professional society news reports and membership recruitment.

Undoubtedly, other applications will be developed.

To this point, the CHiP Network has circulated a monthly newsletter and a monthly Journal Watch service to its subscribers. The Journal Watch includes abstracts from the previous month for six different subspecialty areas: pediatric cardiology; interventional CHD; EP CHD; CHD surgery; fetal cardiology; and ACHD cardiology. The section editors identify the most important abstracts for the month, and offer a featured commentary on them. Journal Watch is housed on the ACHD Learning Center, so users can examine abstracts on a monthly basis going back 2-3 years.

CHiP’s challenge, and the challenge of congenital heart professionals with an interest in the success of this resource, is to grow the network of subscribers and to

“The CHiP Network has the capacity to send information only to certain types of professionals, in certain countries or cities, and to subscribers requesting messages in languages other than English. The potential of the system is still being explored.”

HOW WE OPERATE

The team involved at C.H.I.M.S. is largely a volunteering group of physicians, nurses and technicians who are involved in caring for children with congenital heart disease.

The concept is straightforward. We are asking all interested catheter laboratories to register and donate surplus inventory which we will ship to help support CHD mission trips to developing countries.

Volunteer / Get Involved
www.chimsupport.com

<table>
<thead>
<tr>
<th>Geographic Distribution by Continent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continent</td>
</tr>
<tr>
<td>North America</td>
</tr>
<tr>
<td>Europe</td>
</tr>
<tr>
<td>Asia-Pacific</td>
</tr>
<tr>
<td>Middle East</td>
</tr>
<tr>
<td>Central &amp; South America</td>
</tr>
<tr>
<td>Africa</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Profession Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Work Name Type</td>
</tr>
<tr>
<td>Cardiologist</td>
</tr>
<tr>
<td>Cardiac Care Associate / PA / RN</td>
</tr>
<tr>
<td>Cardiac Surgeon</td>
</tr>
<tr>
<td>Cardiac Anesthetist</td>
</tr>
<tr>
<td>Nurse Practitioner</td>
</tr>
<tr>
<td>Cardiac Intensivist</td>
</tr>
<tr>
<td>Echo Technician</td>
</tr>
<tr>
<td>Researcher / Scientist</td>
</tr>
<tr>
<td>Administrator</td>
</tr>
<tr>
<td>Industry Representative</td>
</tr>
</tbody>
</table>

Volunteer / Get Involved
www.chimsupport.com

HOW WE OPERATE

The team involved at C.H.I.M.S. is largely a volunteering group of physicians, nurses and technicians who are involved in caring for children with congenital heart disease.

The concept is straightforward. We are asking all interested catheter laboratories to register and donate surplus inventory which we will ship to help support CHD mission trips to developing countries.
enhance the value of the service. CHiP has over 25 partner organizations. Each of these is asked to invite its members to join CHiP, and to show informational material about CHiP at their meetings.

To this point, we are grateful that financial support has been provided by Cincinnati Children’s Hospital Heart Institute. We are also introducing a new category of partners, Institutional Partners. The first of these to be identified is Toronto’s Hospital for Sick Children, with 58 subscribers to date.

Join CHiP - membership is free - www.chipnetwork.org

"CHiP’s challenge, and the challenge of congenital heart professionals with an interest in the success of this resource, is to grow the network of subscribers and to enhance the value of the service."

Gary Webb, MD
Cincinnati Adult Congenital Heart Program
The Heart Institute at Cincinnati Children’s Hospital Medical Center
Ph: 513-803-4244; Cell: 215-313-8058
Fax: 513-803-0079
gary.webb@cchmc.org

Table 3. Geographic Distribution by County Distribution

<table>
<thead>
<tr>
<th>Countries</th>
<th>Countries</th>
<th>Countries</th>
<th>Countries</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>1485</td>
<td>Malaysia</td>
<td>16</td>
<td>Greece</td>
</tr>
<tr>
<td>Canada</td>
<td>240</td>
<td>Belgium</td>
<td>15</td>
<td>Poland</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>137</td>
<td>Denmark</td>
<td>14</td>
<td>Slovakia</td>
</tr>
<tr>
<td>Australia</td>
<td>94</td>
<td>China</td>
<td>14</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>58</td>
<td>Israel</td>
<td>13</td>
<td>Sudan</td>
</tr>
<tr>
<td>South Africa</td>
<td>50</td>
<td>Korea, Republic of</td>
<td>13</td>
<td>Ghana</td>
</tr>
<tr>
<td>Brazil</td>
<td>46</td>
<td>Turkey</td>
<td>12</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>India</td>
<td>46</td>
<td>Venezuela</td>
<td>10</td>
<td>Morocco</td>
</tr>
<tr>
<td>Netherlands</td>
<td>37</td>
<td>Colombia</td>
<td>10</td>
<td>Bangladesh</td>
</tr>
<tr>
<td>Iran, Islamic Republic of</td>
<td>28</td>
<td>United Arab Emirates</td>
<td>10</td>
<td>Unspecified</td>
</tr>
<tr>
<td>Sweden</td>
<td>28</td>
<td>France</td>
<td>10</td>
<td>Costa Rica</td>
</tr>
<tr>
<td>Argentina</td>
<td>24</td>
<td>Pakistan</td>
<td>10</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>Egypt</td>
<td>24</td>
<td>Philippines</td>
<td>10</td>
<td>Iraq</td>
</tr>
<tr>
<td>Switzerland</td>
<td>24</td>
<td>Qatar</td>
<td>9</td>
<td>Oman</td>
</tr>
<tr>
<td>Japan</td>
<td>24</td>
<td>Hungary</td>
<td>9</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>Germany</td>
<td>21</td>
<td>Russian Federation</td>
<td>9</td>
<td>Finland</td>
</tr>
<tr>
<td>New Zealand</td>
<td>21</td>
<td>Austria</td>
<td>7</td>
<td>Tanzania, United Republic of</td>
</tr>
<tr>
<td>Thailand</td>
<td>21</td>
<td>Chile</td>
<td>6</td>
<td>Singapore</td>
</tr>
<tr>
<td>Italy</td>
<td>20</td>
<td>Kenya</td>
<td>6</td>
<td>Nepal</td>
</tr>
<tr>
<td>Norway</td>
<td>20</td>
<td>Lithuania</td>
<td>5</td>
<td>Mongolia</td>
</tr>
<tr>
<td>Indonesia</td>
<td>19</td>
<td>Ukraine</td>
<td>5</td>
<td>Jamaica</td>
</tr>
<tr>
<td>Nigeria</td>
<td>17</td>
<td>Portugal</td>
<td>5</td>
<td>Bahrain</td>
</tr>
<tr>
<td>Taiwan</td>
<td>17</td>
<td>Uganda</td>
<td>5</td>
<td>Jordan</td>
</tr>
<tr>
<td>Mexico</td>
<td>16</td>
<td>Hong Kong</td>
<td>5</td>
<td>Ireland</td>
</tr>
<tr>
<td>Spain</td>
<td>16</td>
<td>Kuwait</td>
<td>4</td>
<td>Cyprus</td>
</tr>
</tbody>
</table>

"CHiP’s challenge, and the challenge of congenital heart professionals with an interest in the success of this resource, is to grow the network of subscribers and to enhance the value of the service.”

Gary Webb, MD
Cincinnati Adult Congenital Heart Program
The Heart Institute at Cincinnati Children’s Hospital Medical Center
Ph: 513-803-4244; Cell: 215-313-8058
Fax: 513-803-0079
gary.webb@cchmc.org

“Education and awareness of the leading killer of young people, HCM, Hypertrophic Cardiomyopathy, through organizing and training in cardiac screening programs for young people everywhere."

Anthony Bates Foundation
428 E. Thunderbird Rd., # 633
Phoenix, AZ 85022
Tel: 602-482-5606
www.AnthonyBates.org
sharon@anthonybates.org

CCT
Introduction

Gerbode Defect is a very rare congenital anomaly described as a communication between the left ventricle and the right atrium. It was named after Frank Gerbode, a surgeon from Stanford University who described his surgical findings in 1958. He reported two types (direct and indirect) depending if the defect lies above or below the tricuspid valve along with the presence of a true ventriculo-atrial communication.1 The pathology may be due to a congenital defect, or can result from trauma, myocardial infarction, endocarditis or even aortic valve replacement.2 It can appear as an isolated lesion, but it has been reported to accompany other congenital lesions. We describe 3 cases of patients who had Gerbode Defect along with other findings noted on echocardiography also with other findings not previously reported.

Case 1

A 31-year-old female came in due to frequent symptoms of palpitations of five months duration accompanied by dyspnea on exertion. Physical examination showed a blood pressure of 100/60 with a heart rate of 82 beats per minute. Auscultation of the chest revealed a 4/6 holosystolic murmur at the 4th intercostal space left sternal border with a thrill. Doppler studies showed a mosaic color flow display going from the left ventricle to the left atrium (Figure 1). This was confirmed by transesophageal echocardiogram (Figure 2). Peak systolic gradient between the left ventricle and the right atrium was measured at 89mmHg. There was no chamber dilatation noted. The patient was started on diuretics and eventually underwent surgical closure of the defect. She was discharged stable and improved.

Case 2

A 25-year-old female was referred to our institution for difficulty of breathing, exertional dyspnea and bipedal edema. Physical examination revealed a 4/6 holosystolic murmur at the 3rd left intercostal space. Peak systolic gradient between the left ventricle and the right atrium was measured at 89mmHg. There was no chamber dilatation noted. The patient was started on diuretics and eventually underwent surgical closure of the defect. She was discharged stable and improved.

Case 3

A 29-year-old female diagnosed with Congenital Heart Disease since 9-years-old complained of palpitations and easy fatigability a week postpartum. Physical examination showed a 4/6 holosystolic murmur at the 3rd left intercostal space. Peak systolic gradient between the left ventricle and the right atrium was measured at 89mmHg. There was no chamber dilatation noted. The patient was started on diuretics and eventually underwent surgical closure of the defect. She was discharged stable and improved.
examination showed a blood pressure of 130/80 and tachypnea at 32 cycles per minute with an oxygen saturation of 95% at room air. She was tachycardic at 32 cycles per minute with an oxygen saturation of 95% at room air. She was tachyphylactic with regular rhythm, with right ventricular heave, single S2, with 4/6 holosystolic murmur at the 2nd left intercostal space, (+) thrill, a 4/6 holosystolic murmur at the 4th left intercostal space and positive for Carvallo’s sign. There was electrocardiographic and x-ray evidence of right atrial enlargement and right ventricular hypertrophy. There was a suspicious mosaic color flow during systole from the left ventricle to the right atrium on transthoracic echocardiogram. Two dimensional and 3D transesophageal echocardiogram confirmed the findings of a direct Gerbode Defect above the tricuspid valve (Figure 5). Transthoracic echocardiogram showed a Patent Ductus Arteriosus (Figure 6) with severe pulmonary hypertension. The left atrium, right atrium, main pulmonary artery and right ventricular had signs of volume and pressure overload and there was mitral valve prolapsed with moderate regurgitation. Additional findings included a mild valvar pulmonic stenosis (Figure 7) with a peak gradient of 20 mmHg. A flap-like structure was likewise noted at the interatrial septum suggestive of Patent Foramen Ovale (PFO). Contrast study demonstrated passage of microbubbles from the RA to the LV and LA and from the PA to the descending aorta indicative of the presence of Gerbode defect, PFO and PDA, respectively.

**Discussion**

Gerbode defects are very rare abnormalities with an incidence of 0.08% of congenital defects. It is primarily caused by an anatomical deficiency of the membranous septum which can be either congenital or acquired. Riemenschneider and Moss devised a classification based on the anatomical relationship of the left ventricle to the right atrium shunt with the tricuspid valve. This anatomical arrangement allows the septal leaflet to divide the membranous ventricular septum into two portions: a supravalvular portion, and an infravalvular portion. A defect in the supravalvular portion results in a direct left ventricle to right atrium communication and a defect below the tricuspid valve represents a perimembranous ventricular septal defect and would normally result in a communication between the left ventricle and the right ventricle then through a defective tricuspid valve into the right atrium. This is termed as an indirect Gerbode Defect. The true (or direct) Gerbode defect is a true left ventricular to right atrial communication and is rarer than the indirect type. All the patients in our series had the true or direct form. In both defects left ventricular to right atrium communication allows shunting of blood to the right atrium during systole. If the communication is large enough, the patient may become symptomatic, and may present with signs of volume overload.

Typical findings are similar to that of a ventricular septal defect, with a harsh systolic murmur accompanied by a thrill. A disproportionate enlargement of the right atrium may be found on radiograph along with features of right atrial abnormality on electrocardiogram. However, definitive diagnosis may not be possible based on these methods only. Two of the cases also presented with other shunt abnormalities, as well as varying degrees of pulmonary hypertension, making the diagnosis clinically challenging.

Echocardiography identifies the location of the defect and color flow imaging can identify the flow pattern from the left ventricle to the right atrium. It is also used to locate the relationship of the defect with respect to the tricuspid valve. Transesophageal echocardiography can reliably distinguish the two types and was also found to impact operative repair. One of the hallmarks of Gerbode ventriculo-atrial defect is a high Doppler gradient between the left ventricle and the right atrium accompanied by right atrial dilation. The echocardiographer must be vigilant as the jet from the Gerbode Defect may be confused with a tricuspid regurgitant jet and can be mistakenly associated with pulmonary hypertension. The presence of normal diastolic pulmonary arterial pressure using pulmonic regurgitation jet is very useful to distinguish the true pulmonary arterial hypertension from high velocity jet in the right atrium caused by Gerbode-type defect. Our second patient had a bidirectional shunt with severe pulmonary hypertension and the tricuspid regurgitation jet was delineated properly from the jet coming from the Gerbode Defect. Our third patient had multiple congenital heart defects. The Gerbode Defect was only suspected on transthoracic echo, while integrating clinical findings of right-sided volume overload. Transesophageal echocardiogram revealed the Gerbode Defect, to go along with the patent ductus arteriosus, a patent foramen ovale and severe pulmonary hypertension. Other imaging modalities such as 3D transesophageal echocardiogram may add incremental diagnostic value by delineating the morphologic nature of the ventricular septal defect and its shape, and showing other structures in their realistic spatial distribution. This may have implications in surgical planning.

Surgical repair is indicated for symptomatic patients with significant shunts and is usually associated with favorable outcomes. Gerbode defects may or may not be associated with other cardiac abnormalities. In the study by Anderson et al they noted concomitant congenital anomalies in six children. One patient had a right aortic arch, one patient had a patent ductus arteriosus, three patients had a left superior vena cava, two patients had an anomalous left hepatic vein. In this series, the first patient had an isolated Gerbode Defect with good functional capacity. The second patient similarly had a patent ductus arteriosus with a bidirectional shunt as well as moderate tricuspid regurgitation and severe pulmonary hypertension. Our third patient had multiple congenital defects. Aside from the Gerbode Defect she also had a Patent Ductus Arteriosus with a PFO, with severe tricuspid regurgitation and mild supravalvar pulmonary stenosis. The findings from the latter two patients have not been previously described in literature. Mechanistically the shunt from the Gerbode Defect may contribute to more right-sided volume overload and pulmonary hypertension. The study by Anderson et al was done in children and had no reported operative or late mortality. The outcomes in patients with multiple and advanced concomitant congenital heart disease is uncertain. We recommended surgical closure for our first patient and further work up (hemodynamic studies) on the latter two cases to determine operative prognosis.

**Conclusion**

Gerbode’s Defect is a very rare congenital anomaly which may occur in isolation or may be associated with other congenital heart defects. It may complicate these conditions and even lead to misinterpreted diagnosis. We reported three cases in our institution.
We are committed to the lifetime management of congenital heart disease.

Transcatheter and Surgical Heart Valves
RVOT Conduits
Ablation Technologies
ICDs
Oxygenators and Filters
Cannulae
Pacemakers
Pulse Oximetry Monitoring for CCHD Screening
3rd Generation PFO, ASD, and PDA Occluders* 
Cerebral/Somatic Monitoring

*These products are not available in the US.
which had a direct type of ventriculoatrial communication. These cases underline the importance of integrating sound clinical assessment, as well as meticulous echocardiographic investigation in order to properly diagnose this unusual anomaly, facilitating surgical planning and determination of optimum management.

Figure 4. Transthoracic echocardiogram short axis view at the level of the pulmonary artery bifurcation tract showing a connection between the pulmonary artery and the aorta.

Figure 5. Transesophageal Echocardiography mid-esophageal short axis view showing an echo drop out at the ventriculoatrial septum between the LVOT and right atrium measuring 0.46 cm in diameter (left) with mosaic color flow display across the ventriculoatrial septum and tricuspid valve. 3D TEE mid-esophageal short axis view showing an echo drop out at the ventriculoatrial septum between the LVOT and right atrium with mosaic color flow display across the ventriculoatrial septum and tricuspid valve.

Figure 6. Transthoracic Echocardiography showing the pulmonic valve in parasternal short axis view with systolic doming motion (left) and continuous flow from the aorta to the pulmonary artery (right).

Figure 7. Transesophageal Echocardiography showing the pulmonic valve in mid-esophageal long axis view during diastole(left)and mosaic color flow display across the pulmonic valve during systole (middle). 3D TEE showing the pulmonic valve in mid-esophageal short axis view during systole (right).
References


MEDICAL MEETING FOCUS

2nd Annual Basic & Advanced Fetal Cardiac Symposium and Workshop
Sep. 10-12, 2015; Chicago, IL
www.FetalCardiacSymposium.com

This symposium will discuss various concepts and common CHD malformations encountered in the fetus, with emphasis on imaging and practical tips for diagnosis. In particular, it will include sessions focusing on the following areas:

- Fetal Cardiovascular Physiology and Pathophysiology
- Latest Guidelines in Prenatal Screening and Red Flags in the Diagnosis of Fetal CHD
- Live Demonstration on Performing a Fetal Echocardiogram
- Practical Tips in the Diagnosis of Commonly Encountered Cardiac Defects
- Evaluation of Fetuses with Borderline Cardiac Findings
- Diagnosis and Management of Fetal Arrhythmia
- Updates on Fetal Genetic Evaluation

The symposium will provide the audience with the unique experience of hands-on and live demonstration sessions, as well as opportunities for the audience to discuss interesting cases and interact with experts in the field. Registrants will have the chance to submit interesting cases to be presented during the course of the symposium.

Hands-on Scanning Workshop: There will be two separate sessions focusing on scanning the fetal heart under the supervision of experienced faculty and using various up-to-date machines.

Participants become familiar with: Identifying Situs; Obtain the 4-chamber View; Demonstrate Pulmonary Venous Flow; Obtain the Right and Left Ventricular Arterial Outflow Tracts View; Obtain the 3-vessel View; Obtain the Arch Views.

Sponsored for CME credit by Rush University Medical Center which designates this live activity for a maximum of 19.25 AMA PRA Category 1 Credit(s)™ & 19.25 Continuing Nursing Education credit(s). This activity is also approved by the Society for Diagnostic Medical Sonography (SDMS), and is eligible for up to 19.25 SDMS credits.

Course Director: Karim A. Diab, MD

Invited and Local Faculty: Ra'id Abdulla, MD; Alfred Abuhamad, MD; Emerio T. Aboliras, MD; Sawsan M. Awad, MD, MSC, John Bokowski, PhD, RDCS, FASE; Massimo Caputo, MD, Mch, FRCS; Lisa Homberger, MD; Edgar Jaeggi, MD; Carolyn Jones, MD, PhD; Michelle Rexilius, RDCS; Mark Sklansky, MD; Wayne Tworetzky, MD; Xavier Pombra, DO; Luciana T. Young, MD
Evolution or Revolution?
Disruptive Thinking, Technology and Innovation In the Treatment of Pediatric Cardiac Disease

Biltmore Hotel, Coral Gables, FL
LIVE MEETING
December 3-6, 2015
Virtual Meeting using iLearn®
with Global Transmission Featuring
Simultaneous Spanish Translation

Faculty:

Redmond Burke, MD
Robert Campbell, MD
Aldo R. Castañeda, MD, PhD
Paul Checchia, MD
Mitchell Cohen, MD
John Costello, MD, MPH
Martin Elliott, MD
Jon Epstein, MD
J. William Gaynor, MD
Rani Gereige, MD
Jeff Jacobs, MD
Tom Karl, MD
John Kheir, MD
Terry King, MD
Narendra Kini, MD
Lisa Kohr, MSN, CPNP
Carole Lannon, MD, MPH
Stacey Lihn
Leo Lopez, MD
Brad Marino, MD, MSCE
Juan-Carlos Muñiz, MD
Richard Ohye, MD
Sara Pasquali, MD
Dan Penny, MD, PhD
Andrew Redington, MD
John Rhodes, MD
Anthony Rossi, MD
Jack Rychik, MD
Steve Schwartz, MD
Girish Shirali, MD
Edward Walsh, MD
Gil Wernovsky, MD

SPONSORED BY:

Nicklaus Children’s Hospital
MIAMI CHILDRENS HEALTH SYSTEM
Heart Program

For more information or to register, please visit: nicklauschildrens.org/heartinnovation

Accreditation Statement: The Miami Children’s Health System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: The Miami Children’s Health System designates this live activity for a maximum of 17 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Faculty/Planner Disclosure Policy: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.
ACUTE KIDNEY INJURY CAN BE A SERIOUS COMPLICATION FOLLOWING HEART SURGERY

Newswise — The anti-inflammatory drug dexamethasone helps prevent serious kidney complications that can arise following heart surgery, according to the results of a randomized clinical trial. The findings, which appeared in an upcoming issue of the Journal of the American Society of Nephrology (JASN), could lead to a change in care for patients during cardiac operations.

Acute Kidney Injury (AKI) is one of the most devastating complications following cardiac surgery. Approximately 1% of patients undergoing cardiac surgery require dialysis to treat severe AKI that arises after surgery, and the incidence is higher among patients with pre-operative chronic kidney disease. These patients experience strikingly high death rates while in the hospital that exceed 40%. “One percent sounds like a small percentage; however, given the fact that each year, over half a million people undergo heart surgery in the United States alone; this means that an estimated 5000 patients develop renal failure, and of those about 2500 die as a result of this complication,” said Kirollos Jacob, MD (University Medical Center, Utrecht, The Netherlands). He noted that these figures are rising due to the aging population.

Because heart surgery initiates an inflammatory reaction in the body that can have negative effects on the kidneys, Dr. Jacob and his colleagues wondered whether giving patients dexamethasone, an anti-inflammatory drug, could decrease the risk of severe AKI following cardiac surgery. The team analyzed the results of a large randomized controlled trial called the Dutch Dexamethasone for Cardiac Surgery (DECS) trial, which included 4465 patients undergoing cardiac surgery who were randomized to receive placebo or dexamethasone during surgery. The original trial tested whether dexamethasone could reduce the risk of a variety of major postoperative complications. In this analysis, the investigators specifically examined kidney failure and focused on the most severe form: AKI requiring dialysis.

Dexamethasone appeared to protect against the development of severe AKI. Patients who received the drug had about a 2.5-times lower risk of developing AKI requiring dialysis compared with those receiving a placebo.

“The beneficial effects of dexamethasone were particularly present in those who already had pre-existing kidney disease before heart surgery,” said Dr. Jacob. “This reinforces the fact that this drug could be of major importance for the increasing elderly population with pre-existing kidney disease undergoing a heart operation.”

The study is the largest randomized, placebo-controlled trial showing a potential benefit of any therapeutic drug for the prevention of severe kidney injury following heart surgery. A single dose of dexamethasone during a heart operation is inexpensive, straightforward, painless, and safe for patients. “These advantages make the intervention very accessible and cost-effective, especially since the costs for dialysis are very high,” said Dr. Jacob.

Study co-authors include David Leaf, MD, MMSc, Jan Dieleman MD, Dieden van Dijk, MD, PhD, Amo Nierich, MD, PhD, Peter Rosseel, MD, PhD, Joost van der Maaten, MD, PhD, Jan Hofland, MD, PhD, Jan Diephuis, MD, Felly de Lange, MD, PhD, Christine Boer, PhD, Jolanda Kluit, MD, PhD, Sushrut Waikar, MD, MPH, for the Dexamethasone for Cardiac Surgery (DECS) Study Group.

Disclosures: The DECS study was sponsored by grants from the Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Heart Foundation.

The article, entitled “Intraoperative High-Dose Dexamethasone and Severe Acute Kidney Injury after Cardiac Surgery,” appeared online at http://jasn.asnjournals.org/ on May 7, 2015.

Founded in 1966, and with more than 15,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

HOSPITAL TO CREATE EMERGENCY EXPERIENCES USING VIRTUAL REALITY: WALK AROUND INSIDE CRISIS SITUATIONS, EDUCATE MEDICAL PROFESSIONALS

Next Galaxy Corp (OTC: NXGA) recently announced the signing of an agreement with Miami Children's Hospital. Next Galaxy will develop immersive Virtual Reality medical instructional content for patient and medical professional education using the Company's VR Model. Per the multi-year agreement, Next Galaxy and Miami Children's Hospital are jointly creating VR Instructionals on cardiopulmonary resuscitation (CPR) and other lifesaving procedures, which will be released as an application for smartphones.
Incorporating eye gaze control, gestures, and voice commands while "walking around" inside an emergency medical experience or crisis, Next Galaxy's Virtual Reality Model engages participants far beyond today's methodology of passively watching video and taking written tests.

"Assessments are incorporated directly into the medical VR models. We will design situations where participants are required to make the appropriate decisions about proper techniques. The Virtual CPR instructional will measure metrics and provide real-time feedback ensuring participants accurately perform CPR techniques. Further, the instructional will explain any mistake and prompt users to try again when errors are made. Supportive messages are delivered upon success," states Mary Spio CEO, Next Galaxy Corp.

The medical VR models will be viewable through smartphones and desktops as 3D, and via VR devices such as Google Cardboard, VRONE and Oculus Rift.

For further information, visit www.nextgalaxycorp.com.

Higher Activity Levels Increase Survivability of ICD Patients

Patients who had higher activity levels following ICD implantation had better survival, according to research in the Journal of the American Heart Association. The research will be simultaneously presented at the Heart Rhythm Society 2015 Scientific Sessions.

An implantable cardioverter-defibrillator (ICD) is a battery-powered device that typically combines a "generator" placed under the skin near the shoulder with a wire that is inserted into the heart through the vein beneath the collarbone. ICDs are very effective at recognizing fast, potentially life-threatening heart rhythm disorders and providing timely shocks that restore a normal rhythm. However, many patients who receive ICDs may still be at risk of dying from progression of their underlying heart disease or other problems.

In the largest study on the relationship between activity and survival in ICD patients, researchers analyzed how active participants were in the first 30-60 days after implantation and then over time up to four years. ICDs collect patients' daily activity automatically using sensors embedded in the device itself, which determines whether patients are active or not on a minute-by-minute basis. "Active" measured in this way means approximately a walking speed of 2 miles an hour.

Researchers found that patients in the most active group after getting an ICD had a 40% absolute lower risk of death at four years compared to patients who had engaged in the least activity. Regardless of age, gender or device type, lower average activity during the first 30-60 days was independently associated with a 44% higher risk of death over time. A similar analysis looking at activity over several years demonstrated a similar risk of death for each 30 minutes' difference in activity. "We expected to see a difference, but we were struck by the magnitude of these results," said Daniel B. Kramer, MD, MPH, lead author of the study and Assistant Professor of Medicine at Harvard Medical School in Boston, MA.

"Patients' functional status clearly predicts survival. Our hope would be to use activity as a factor in not just predicting outcomes but also to guide strategies that may improve outcomes. But that is much further down the line."
The NuDEL™ Stent Delivery System is designed for the efficient and effective treatment of Coarctation of the Aorta.

The NuDEL includes a triaxial balloon in balloon designed catheter with a Covered Mounted CP Stent™, which is then covered by a sheath as an all-in-one system. Combining the proven technologies of our NuMED BIB® balloon catheter and our Covered CP Stent™, the NuDEL System employs both our compact delivery method and the “zig” pattern stent design.

The NuDEL System is available for immediate purchase in the EU. Contact us or your local distributor to place an order.
Researchers studied the ALTITUDE registry, a nationwide database that involved 98,437 patients enrolled in a remote monitoring program. About 57% of the patients had received a new or replacement ICD and 43% had received cardiac resynchronization therapy (CRT-D) devices in 2008-12. CRT-D therapy combines an ICD with cardiac resynchronization therapy. Patients were followed for a median 2.2 years.

“What is intriguing about our results is that looking at just one piece of information collected automatically after a device is implanted provides very powerful prognostic information about how they are likely to do over the next several years,” Kramer said.

The major limitation of the analysis, researchers noted, is that this study design only supports describing an association between activity and survival. Further studies are needed to test strategies aimed at promoting activity or using this information to change patients’ treatment.

Co-authors are: Susan L. Mitchell, MD, MPH; Joao Monteiro, PhD; Paul W. Jones, MS; Sharon-Lise Normand, PhD; David L. Hayes, MD; and Matthew R. Reynolds, MD, M.Sc. Author disclosures and funding information are on the manuscript. The ALTITUDE study is supported by Boston Scientific.

Tiny Heart, Big Promise - Understanding How Cells Become Coronary Vessels May Lead to Advances in Repairing Heart Damage

Newswise — The heart has its own dedicated blood supply, with coronary arteries that supply oxygen-rich blood to the heart and cardiac veins that remove deoxygenated blood. This system of vessels nourishes the heart, enabling it to pump blood to all the other organs and tissues of the body. Yet despite their critical importance, the process and molecules required for coronary vessel development have not been fully determined.

Studying zebrafish, investigators at The Saban Research Institute and the Heart Institute of Children’s Hospital Los Angeles discovered a new source for cells that can develop into coronary vessels and have identified the signaling protein, a chemokine called CXCL12, which guides this process. Results of the study was published online May 26th by the journal Developmental Cell.

Zebrafish have emerged as an important vertebrate model for cardiovascular research for a number of reasons, including the ability to regenerate its heart if damaged, and because the transparency of the embryos allows easy observation of internal processes like blood vessel development. Using confocal and time-lapse imaging, the investigators were able to visualize coronary vessels developing from the endocardium, or the inner lining of the heart – specifically from the atrioventricular canal – the structure that divides the heart into compartments.

“This furthers our efforts into heart regeneration to repair human hearts,” said Ching-Ling (Ellen) Lien, PhD, principal investigator at The Saban Research Institute of CHLA and senior author on the paper. “We have now found a novel source of cells that can differentiate into coronary vessels and have identified the factors required.”

Lien and her team observed that zebrafish with a mutation at the CXCR4 receptor survive, but are not able to form coronary vessels or undergo heart regeneration following injury. Since fish without this mutation are able to do both, the investigators concluded that an interaction between CXCR4 receptors on endothelial cells and the CXCL12b protein expressed by the myocardium regulate the process. In addition to providing basic information about the developing heart, this finding may also have clinical relevance.

“Children or young adults may not be aware of having abnormal coronary vessels because their circulation is adequate until the heart is stressed by increased demands, for instance when participating in strenuous sports,” explains Lien, who is also an assistant professor at the Keck School of Medicine and an investigator at the Cardiovascular Thoracic Institute, both at the University of Southern California. “Then suddenly, an apparently healthy, young person dies. Alternatively, a person with abnormal coronary vessels might have higher risk of experiencing heart attacks later on in life. Our findings will guide future study toward understanding these devastating conditions in order to be better able to diagnose them and develop intervention strategies.”

The first author, Dr. Michael R.M. Harrison is a CIRM scholar and Saban RCDF fellow. Additional contributors include Ying Huang and Arthela Osorio, The Saban Research Institute of CHLA; Jeroen Bussmann and Arndt F. Siekmann, Max Planck Institute for Molecular Biomedicine, Muenster, Germany; Long Zhao, C. Geoffrey Burns and Caroline E. Burns, Harvard Medical School; and Henry M. Sucov, Broad Center for Regenerative Medicine and Stem Cell Research at USC.

The study was supported in part by the National Heart, Lung and Blood Institute R01HL06121, The Saban Research Institute Career Development Award, and a California Institute for Regenerative Medicine (CIRM) postdoctoral fellowship TG2-01168.

For more information, visit CHLA.org.

© 2015 by Congenital Cardiology Today (ISSN 1554-7787-print; ISSN 1554-0499-online). Published monthly. All rights reserved. www.CongenitalCardiologyToday.com

8100 Leawood Way, PO Box 444, Manzanita, OR 97130 USA
Tel: +1.301.279.2005; Fax: +1.240.465.0692

Publishing Management:
Tony Carlson, Founder, President & Sr. Editor - TCarlsonmd@gmail.com
Richard Koubianis, Group Publisher & Editor-in-Chief - RichardK@CCT.bz
John W. Moore, MD, MPH, Group Medical Editor - JMoore@RCHSD.org

Editorial Board: Teiji Akagi, MD; Zohair Al Halees, MD; Mazeni Aliw, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; John Lambert, MD; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshio Nakanishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD, PhD; James C. Perry, MD; P. Syamasundar Rao, MD; Shaakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hideshi Tomita, MD; Gil Wernovsky, MD; Zhuming Xu, MD, PhD; William C. L. Yip, MD; Carlos Zubal, MD

Free Subscription to Qualified Professionals: Send your name, title(s), hospital or practice name, work address and url, phone, fax and email to: sub@cct.bz.

Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.
Fetal Cardiology Opportunity
Health care is transforming. We’re transforming health care.

Join Us

If you are an experienced fetal cardiologist interested in joining a progressive practice, consider Arizona Pediatric Cardiology (APC). APC, in affiliation with Phoenix Children’s Hospital (PCH), provides state-of-the-art, comprehensive inpatient and outpatient pediatric cardiology services throughout the state of Arizona. Phoenix Children’s Hospital, ranked 16th by the U.S. News and World Report, has 24 CVICU beds and two cardiothoracic surgeons who perform over 500 surgeries annually.

Help grow our already large fetal heart program and collaborate with maternal-fetal medicine and neonatology practices in the Phoenix metro area. As a leader in fetal cardiology, our practice sponsors the Annual Phoenix Fetal Cardiology Symposium and is a participating site in multiple fetal cardiology multi-center trials.

This is an excellent opportunity to be a part of a team of echocardiographers who perform and interpret transthoracic and transesophageal echocardiograms in an IAC-accredited lab. Clinical responsibilities also include inpatient and outpatient general pediatric cardiology care.

In addition to fetal cardiology, APC provides a wide range of services and programs including interventional and diagnostic catheterization, electrophysiology/ablations, cardiac imaging (MRI), adult congenital heart disease program, anti-coagulation program, preventive cardiology, heart transplant/heart failure program and a metabolic stress lab.

About Phoenix

Wide variety of cultural and sporting events
California coast within a day’s drive
Diverse geography offers desert, lake and mountain recreational activities
310 days of sunshine per year
Family-oriented community
Excellent school districts
Unlimited activities for children

Candidate requirements:

✓ A minimum of three years’ experience
✓ A fourth year of fellowship in advanced imaging training, including fetal echocardiography, preferred

Strength in numbers

25 pediatric cardiologists, including
5 fetal cardiologists
5 fetal sonographers
2 advanced practice fetal cardiac nurse coordinators
5 office locations
More than 1,500 fetal echocardiograms performed last year

LEARN MORE

www.pediatrix.com/clinicalcareers
800.243.3839, ext. 5589

Arizona Pediatric Cardiology is an affiliate of Cardiology Specialists Pediatrix
At Toshiba, we go beyond listening and give you a voice. Because understanding your business is our business, your challenges become our challenges, and together, we find creative ways to solve them. With decades of experience and groundbreaking technology built into all of our products, you can see you’re actually being heard. It’s not just lip service.